Geneva, May 4 -- International Clinical Trials Registry received information related to the study (CTRI/2026/04/109059) titled 'A study of low-dose nivolumab with standard chemotherapy in patients with advanced Hodgkin lymphoma who do not show a good early response to treatment' on April 22.
Study Type: Interventional
Study Design:
Single Arm Study Method of generating randomization sequence:Not Applicable Method of allocation concealment:Not Applicable Blinding and masking:Open Label
Primary Sponsor: Tata Memorial Centre
Condition:
Health Condition 1: C00-D49- Neoplasms
Intervention:
Intervention1: Nivolumab, Doxorubicin, Vinblastine, Dacarbazine: Low dose Nivolumab 40 mg IV plus AVD regimen Doxorubicin 25 mg per m2 IV Vinbla...